TRANSLATE

The aml Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the aml Hub cannot guarantee the accuracy of translated content. The aml and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

The AML Hub is an independent medical education platform, sponsored by Astellas, Daiichi Sankyo, Johnson & Johnson, Kura Oncology and Syndax, and has been supported through educational grants from Bristol Myers Squibb and the Hippocrate Conference Institute, an association of the Servier Group. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.

Now you can support HCPs in making informed decisions for their patients

Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.

Find out more

Intensive induction shows greater remission rates and better OS compared to nonintensive induction for patients with intermediate- or adverse-risk AML

By Oscar Williams

Share:

Feb 24, 2022


During the 63rd American Society of Hematology (ASH) Annual Meeting and Exposition, Gail Roboz, Weill Cornell Medicine, New York, US, presented results from the study Connect® Myeloid Disease Registry (NCT01688011), investigating post remission treatment patterns and outcomes for patients with acute myeloid leukemia (AML) in a real-world cohort.1 Remission and overall survival (OS) rates remain low in AML despite advances in treatment options.

Study design

The large, prospective, multicenter, observational cohort included patients aged ≥55 years who had been diagnosed with AML within 60 days of enrolment. Patient categories were set out according to the European LeukemiaNet (ELN) 2010 genetic prognostic factor: favorable; intermediate; adverse.

Results

Across a total of 706 patients, 313 received intensive therapy and 393 received nonintensive therapy. The median OS by age and ELN 2010 category is shown in Table 1.

Table 1. Median OS across both treatment groups*

ELN, European LeukemiaNet; NE, not evaluable; OS, overall survival.
*Adapted from Roboz et al.1

Median OS,
months (95% CI)

Intensive therapy
(n = 313)

Nonintensive therapy
(n = 393)

Whole group

22 (18–29)

11 (9–13)

By age

              <60 years

38 (23–NE)

16 (9–NE)

              ≥60 to <70 years

24 (17–40)

13 (8–18)

              ≥70 years

14 (9–21)

10 (9–13)

By ELN 2010 risk

              Favorable

54 (34–NE)

16 (6–NE)

              Intermediate

26 (21–38)

14 (11–17)

              Adverse

8 (7–11)

6 (5–8)

The most common consolidation therapy for patients in the intermediate-/adverse-risk categories was cytarabine. 42 (54.5%) patients in the intermediate-/adverse-risk categories who received consolidation underwent transplantation, compared to 8 (22.8%) patients with favorable risk. The median time from first remission to transplantation was 3.8 months for patients in the intermediate-/adverse-risk categories, compared to 9.6 months for those in the favorable risk. The number of patients who achieved remission for each treatment group is shown in Figure 1.

Figure 1. Patients who achieved remission*

*Adapted from Roboz et al.1

 Among the 261 patients achieving remission regardless of therapy, 161 had intermediate/adverse risk. Among these patients, 100 were not suitable for transplant due to age, comorbidities, and performance status. Most patients who did not undergo transplantation had some type of post remission therapy (see Table 2).

Table 2. Post remission therapy for patients who did not undergo transplantation*

*Adapted from Roboz et al.1

Post remission therapy

Patients, n
(n = 100)

Consolidation—intensive chemotherapy

35

Prolonged therapy—ongoing therapy with similar agents used in low-intensity induction

27

Maintenance therapy—low-intensity agent not used during induction or consolidation

16

No post remission therapy

22

Conclusion

Treatment outcomes were consistent with expectations based on published data. Patients with ELN intermediate/adverse risk were unable to receive a transplant and, therefore, continued to have poor OS despite receiving post remission therapy.

References

Please indicate your level of agreement with the following statements:

The content was clear and easy to understand

The content addressed the learning objectives

The content was relevant to my practice

I will change my clinical practice as a result of this content